ArticleScientifica2025
Mapping the Landscape of Anti-Breast Cancer Drug Discovery in Saudi Arabia: A Bibliometric Analysis (2019-2023).
Article in Scientifica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, the most prevalent cancer worldwide, poses a significant public health challenge, especially in the advanced stages. According to the Saudi Health Council (2020), breast cancer is also the leading cancer in Saudi Arabia with recent increases in incidence rates. Over the past two decades, Saudi Arabia has made significant advancements in anti-breast cancer drug discovery driven by increased research funding, improved access to scientific resources, and enhanced education. This study aims to highlight Saudi Arabia's contributions to this field through a bibliometric analysis of anti-breast cancer drug discovery research published between 2019 and 2023. Using a comprehensive search strategy, 943 publications were retrieved from the Web of Science Core Collection (WoSCC) database and analyzed. Bibliometric tools such as VOSviewer and Microsoft Excel were used to highlight trends in publication output, research areas, and collaboration networks. The results reveal a steady increase in Saudi publications, rising from under 100 in 2019 to over 250 in 2023. The primary research areas were Chemistry (43.69%), Pharmacology/Pharmacy (23.65%), and Biochemistry (22.80%). Elsevier and MDPI were the leading publication platforms, while King Saud University was identified as the primary source of research funding (17.60%). Co-authorship networks revealed strong collaborations between Saudi institutions and international partners. The most frequent keywords reflected key research priorities within Saudi institutions, "anticancer", "molecular docking", and "nanoparticles". The most commonly studied therapeutic targets were EGFR, Caspase, and VEGF with a diverse range of therapeutic approaches including pyrimidines, nanoparticles, and natural products. This analysis highlights Saudi Arabia's growing contributions to the field of breast cancer drug discovery and provides a foundation for future research and collaboration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.